Dr. Kasi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2330 Shawnee Mission Pkwy
Stop 5003
Westwood, KS 66205Phone+1 913-588-6029Fax+1 913-588-9822
Education & Training
University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2012 - 2015- University of Kansas School of MedicineFellowship, Gastro Intestinal Medical Oncology, 2014 - 2014
- University of Kansas School of MedicineResidency, Internal Medicine, 2009 - 2012
University of TexasPublic Health, 2008 - 2009
Bangalore Medical CollegeClass of 2008
Certifications & Licensure
KS State Medical License 2015 - 2025
MO State Medical License 2021 - 2025
Awards, Honors, & Recognition
- Junior Faculty Travel Award for poster presentation KU Cancer Center, 2016
- Fellow Grant to attend Coagulation Disorder Workshop Hemostasis and Thrombosis Research Society, 2013
- Second prize in oral presentation at ACP plenary session American College of Physicians, 2010
- Join now to see all
Clinical Trials
- Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial Start of enrollment: 2019 Jan 22
- Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer Start of enrollment: 2019 May 10
- Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine Start of enrollment: 2019 Jan 14
Roles: Study Chair, Contact
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsDevimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: ...Philip A Philip, Vaibhav Sahai, Nathan Bahary, Amit Mahipal, Anup Kasi
Journal of Clinical Oncology. 2024-11-01 - Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.Daniel H Ahn, Maya Ridinger, Timothy L Cannon, Lawrence Mendelsohn, Jason S Starr
Journal of Clinical Oncology. 2024-10-30 - 2 citationsAssociation of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.Gregory P Botta, Maen Abdelrahim, Ronald L Drengler, Vasily N Aushev, Abdullah Esmail
The Oncologist. 2024-10-03
Press Mentions
Targovax Announces Dosing of First Subject with TG01 for Pancreatic CancerMarch 15th, 2023- Center Creating Rapid Next-Gen Medical Tests Wins $6.6M NIH FundingMay 12th, 2022
- Panavance Announces Abstract and Poster at ASCO Gastrointestinal Cancers Symposium, Providing an Update on the Status of GP-2250 Clinical Trial in Pancreatic Cancer PatientsJanuary 19th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
